Luke Piggott
Overview
Explore the profile of Luke Piggott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davies J, Marlow G, Uusi-Kerttula H, Seaton G, Piggott L, Badder L, et al.
Viruses
. 2021 Jun;
13(5).
PMID: 34066836
We previously developed a refined, tumor-selective adenovirus, Ad5-A20, harboring tropism ablating mutations in each major capsid protein, to ablate all native means of infection. We incorporated a 20-mer peptide (A20)...
2.
Soukupova J, Bordoni C, Turnham D, Yang W, Seaton G, Gruca A, et al.
Mol Cancer Ther
. 2021 Mar;
20(5):775-786.
PMID: 33649105
The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths. Current antimetastatic treatment options...
3.
Healey G, Pan-Castillo B, Garcia-Parra J, Davies J, Roberts S, Jones E, et al.
J Immunother Cancer
. 2019 Oct;
7(1):280.
PMID: 31665084
Background: The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required. Methods:...
4.
Piggott L, Silva A, Robinson T, Santiago-Gomez A, Simoes B, Becker M, et al.
Clin Cancer Res
. 2018 Jan;
24(10):2452-2463.
PMID: 29363524
One third of ER-positive breast cancer patients who initially respond to endocrine therapy become resistant to treatment. Such treatment failure is associated with poor prognosis and remains an area of...
5.
Chen H, Joalland N, Bridgeman J, Alchami F, Jarry U, Khan M, et al.
Immunol Cell Biol
. 2017 Mar;
95(7):620-629.
PMID: 28356569
The inherent resistance of cancer stem cells (CSCs) to existing therapies has largely hampered the development of effective treatments for advanced malignancy. To help develop novel immunotherapy approaches that efficiently...
6.
Piggott L, Omidvar N, Marti Perez S, French R, Eberl M, Clarkson R
Breast Cancer Res
. 2015 Jul;
17:96.
PMID: 26177636
No abstract available.
7.
Smalley M, Piggott L, Clarkson R
Cancer Lett
. 2012 May;
338(1):57-62.
PMID: 22554712
Only a fraction of the cells in a breast tumour are able to seed new tumour growth. These so-called breast cancer stem cells (bCSCs) are characterised by a number of...
8.
Piggott L, Omidvar N, Marti Perez S, French R, Eberl M, Clarkson R
Breast Cancer Res
. 2011 Sep;
13(5):R88.
PMID: 21914219
Introduction: It is postulated that breast cancer stem cells (bCSCs) mediate disease recurrence and drive formation of distant metastases - the principal cause of mortality in breast cancer patients. Therapeutic...